RxDoctor Payments Data

Timothy Rop, MD

Family Medicine · Inman, SCNPI 1447220348

Payments from drug & device makers

$607in general payments, 2019–2025

Across 39 payments — averaging $15.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$140
  • Novo Nordisk$77
  • Abbott$73
  • Pfizer$56
  • Dexcom, Inc.$55
  • Sanofi-aventis U.S. LLC$47
  • plus $159 from 7 others

What the payments were for

  • Food & beverage$607100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$607 in reported general payments places this provider in the 50th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$138,069
Medicare patients
276
Services billed
2,731

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide126$224,800
JardianceEmpagliflozin135$168,729
EliquisApixaban97$123,345
XareltoRivaroxaban44$57,340
JanuviaSitagliptin Phosphate38$41,470
TrulicityDulaglutide24$40,128
Breo ElliptaFluticasone/Vilanterol34$26,061
FarxigaDapagliflozin Propanediol25$21,752
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog43$19,680
JanumetSitagliptin Phos/Metformin Hcl22$19,369
MyrbetriqMirabegron25$19,159
Tresiba Flextouch U-100Insulin Degludec15$14,704
Lantus SolostarInsulin Glargine,hum.Rec.Anlog73$10,708
SymbicortBudesonide/Formoterol Fumarate20$10,443
Atorvastatin Calcium867$8,219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$77$224,800126 claims
PfizerEliquis$56$123,34597 claims
Johnson & JohnsonXarelto$15$57,34044 claims
Lilly USA, LLCTrulicity$40$40,12824 claims
GSKBreo Ellipta$26$26,06134 claims
Astellas Pharma US IncMyrbetriq$29$19,15925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Inman

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →